NanoMedSyn is a biopharmaceutical Deep Tech company focused on the creation and the development of innovative therapeutics using targeted vectors. The company discovers, develops and selects vectors with site-specific conjugation to engineer different types of therapeutics. Its proprietary technology has been optimized for safety, efficacy and biophysical properties.
Year of creation: 2012
Line of business: Biotechnology
Institut Curie: Behind the technology
NanoMedSyn develops multiple engineered synthetic derivatives of mannose 6-phosphate, called AMFA, that bind a specific receptor: the membrane mannose 6-phosphate receptors (M6PR). M6PR represents the major pathway for the cellular entry and the lysosomal addressing. Adding our AMFA tags on proteins, cytotoxic agents or nanoparticles offers a unique solution to unmet clinical needs.
NanoMedSyn shares its platform for the development of new targeted therapies for potential applications on cancer, metabolic, inflammatory and autoimmune diseases.